XML 49 R40.htm IDEA: XBRL DOCUMENT v3.26.1
Significant Collaborative Research and License Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2024
Dec. 31, 2021
Sep. 30, 2021
Oct. 31, 2017
Jun. 30, 2026
Dec. 31, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2022
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2017
Dec. 31, 2016
Mar. 31, 2026
Dec. 31, 2024
Apr. 30, 2024
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Research and development         $ 68,036   $ 62,227       $ 126,881 $ 123,863          
Net sales                     150,000            
Other Receivables, net         2,703 $ 6,404         2,703           $ 3,500
Allergan License Agreement [Member] | Vitae Pharmaceuticals Inc [Member]                                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Research and development                         $ 5,000        
Potential milestone payments to be made       $ 99,000                          
Aggregate potential milestone payable       $ 70,000                          
Milestone Expenses Paid           12,000                   $ 18,000  
Development and regulaotry milestones Expenses         38,000           38,000            
License expiration year       10 years                          
Ucb License Agreement [Member] | U C B Biopharma [Member]                                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Research and development               $ 10,000 $ 15,000   41,000     $ 5,000      
Potential milestone payments to be made                           119,500      
Aggregate potential milestone payable                           $ 250,000      
Milestone Expenses Paid         150,000           150,000            
License expiration year                           10 years      
Milestone payment payable           10,000       $ 5,800              
Collaboration And License Agreement [Member]                                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Milestone payment received $ 12,500                                
Other Receivables, net                             $ 5,000    
Common stock shares purchased   1,421,523                              
Purchase price per share   $ 24.62                              
Proceeds from issuance of common stock   $ 35,000                              
Collaboration receivable         26,400 28,100         26,400            
Collaboration revenue         18,100   $ 9,400       34,000 $ 9,100          
Collaboration expense due to counterparty         $ 4,000 $ 4,400         $ 4,000            
Collaboration And License Agreement [Member] | Maximum [Member]                                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Potential milestone payments to be made   220,000                              
Commercialization milestones and tiered royalties   230,000                              
Collaboration And License Agreement [Member] | Non-Refundable Cash Payments [Member]                                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Upfront milestone payable   $ 117,000                              
Global and U.S. [Member] | Collaboration And License Agreement [Member]                                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Development costs associated with clinical trials     45.00%                            
Global and U.S. [Member] | Collaboration And License Agreement [Member] | Incyte Corporation [Member]                                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Development costs associated with clinical trials     55.00%                            
Ex-U.S. Countries [Member] | Collaboration And License Agreement [Member]                                  
Research And Development Arrangement Contract To Perform For Others [Line Items]                                  
Development costs associated with clinical trials     100.00%